Tumor-Induced Osteomalacia: an Up-to-Date Review

Current Rheumatology Reports

Volumn 17, Issue 6, 2015, Pages

  Hautmann, Anke H ^a   Hautmann, Matthias G ^a   Kölbl, Oliver ^a   Herr, Wolfgang ^a   Fleck, Martin ^a,b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b Asklepios Clinic   (Germany)

Author keywords

FGF23; Giant cell tumor; Hemangiopericytoma; Hypophosphatemia; Paraneoplastic disorder; Phosphaturic mesenchymal tumor mixed connective tissue variant; Radiotherapy; Somatostatin receptor 2A; Tumor induced osteomalacia

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; OCTREOTIDE; PHOSPHATE; VITAMIN D;

CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CHEMORADIOTHERAPY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; ELECTRON MICROSCOPY; HISTOPATHOLOGY; HUMAN; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; MESENCHYMOMA; METASTASIS; ONCOGENIC OSTEOMALACIA; PATHOGENESIS; PHOSPHATE URINE LEVEL; PHOSPHATURIA; PHOSPHATURIC MESENCHYMAL TUMOR MIXED CONNECTIVE TISSUE VARIANT; REVIEW; COMPLICATION; NEOPLASMS, CONNECTIVE TISSUE; PARANEOPLASTIC SYNDROMES; PROGNOSIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MESENCHYMOMA; NEOPLASMS, CONNECTIVE TISSUE; PARANEOPLASTIC SYNDROMES; PROGNOSIS;

EID: 84928654432     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-015-0512-5     Document Type: Review

References (44)

1. Drezner MK. Tumor-induced osteomalacia. Rev Endocr Metab Disord. 2001;2(2):175–86.
2. de Jan Beur SM. Tumor-induced osteomalacia. JAMA: J Am Med Assoc. 2005;294(10):1260–7.
3. White KE, Larsson TE, Econs MJ. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev. 2006;27(3):221–41.
4. Kaul M, Silverberg M, DiCarlo E, et al. Tumor-induced osteomalacia. Clin Rheumatol. 2007;26(9):1575–9.
5. Rendina D, de Filippo G, Tauchmanovà L, et al. Bone turnover and the osteoprotegerin–RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases. Calcif Tissue Int. 2009;85(4):293–300.
6. Carpenter T. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab. 2012;30(1):1–9.
7. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28 (1).
8. Woo VL, Landesberg R, Imel EA, et al. Phosphaturic mesenchymal tumor, mixed connective tissue variant, of the mandible: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(6):925–32.
9. Mori Y, Ogasawara T, Motoi T, et al. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(3):e57–63.
10. Chong WH, Molinolo AA, Chen CC, et al. Tumor-induced osteomalacia. Endocr-Relat Cancer. 2011;18(3):R53–77. Worth reading overview about the literature and the differential diagnosis of TIO.
11. Chong WH, Yavuz S, Patel SM, et al. The importance of whole body imaging in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2011;96(12):3599–600.
12. Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10(11):662–70.
13. Rowe PSN. The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med. 2004;15(5):264–81.
14. Imanishi Y, Hashimoto J, Ando W, et al. Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia. J Bone Miner Metab. 2012;30(1):93–9.
15. Leaf DE, Pereira RC, Bazari H, et al. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J Clin Endocrinol Metab. 2013;98(3):887–91.
16. Honda R, Kawabata Y, Ito S, et al. Phosphaturic mesenchymal tumor, mixed connective tissue type, non-phosphaturic variant: report of a case and review of 32 cases from the Japanese published work. J Dermatol. 2014;41(9):845–9. Excellent overview about the recently published literature.
17. Ledford CK, Zelenski NA, Cardona DM, et al. The phosphaturic mesenchymal tumor: why is definitive diagnosis and curative surgery often delayed? Clin Orthop Relat Res. 2013;471(11):3618–25.
18. Duet M, Kerkeni S, Sfar R, et al. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med. 2008;33 (11).
19. Haeusler G, Freilinger M, Dominkus M, et al. Tumor-induced hypophosphatemic rickets in an adolescent boy—clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue. J Clin Endocrinol Metab. 2010;95(10):4511–7.
20. Houang M, Clarkson A, Sioson L, et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol. 2013;44(12):2711–8.
21. Hautmann AH, Schroeder J, Wild P, et al. Tumor-induced osteomalacia: increased level of FGF-23 in a patient with a phosphaturic mesenchymal tumor at the tibia expressing periostin. Case Rep Endocrinol. 2014;2014:729387. Interesting case report with new findings in immunohistochemical stainings and review of the recently published literature.
22. Wilkins GE, Granleese S, Hegele RG, et al. Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab. 1995;80(5):1628–34.
23. Shelekhova K, Kazakov D, Hes O, et al. Phosphaturic mesenchymal tumor (mixed connective tissue variant): a case report with spectral analysis. Virchows Arch. 2006;448(2):232–5.
24. Stone MD, Quincey C, Hosking DJ. A neuroendocrine cause of oncogenic osteomalacia. J Pathol. 1992;167(2):181–5.
25. Malhotra G, Agrawal A, Jambhekar NA, et al. The search for primary tumor in a patient with oncogenic osteomalacia: F-18 FDG PET resolves the conundrum. Clin Nucl Med. 2010;35 (11).
26. Agrawal K, Bhadada S, Mittal BR, et al. Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia. Clin Nucl Med. 2015;40(1):e6–e10.
27. Breer S, Brunkhorst T, Beil FT, et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone. 2014;64:222–7.
28. Fukumoto S. Diagnostic modalities for FGF23-producing tumors in patients with tumor-induced osteomalacia. Endocrinol Metab. 2014;29(2):136–43.
29. Caudell JJ, Ballo MT, Zagars GK, et al. Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys. 2003;57(1):158–65.
30. Kinoshita Y, Fukumoto S. [Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia]. Clin Calcium. 2014;24(8):1217–22.
31. Seufert J, Ebert K, Müller J, et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med. 2001;345(26):1883–8.
32. Ogose A, Hotta T, Emura I, et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol. 2001;30(2):99–103.
33. MORIMOTO T, TAKENAKA S, HASHIMOTO N, et al. Malignant phosphaturic mesenchymal tumor of the pelvis: a report of two cases. Oncol Lett. 2014;8(1):67–71.
34. Mendenhall WM, Zlotecki RA, Scarborough MT, et al. Giant cell tumor of bone. Am J Clin Oncol. 2006;29 (1).
35. Tarasova VD, Trepp-Carrasco AG, Thompson R, et al. Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy. J Clinical Endocrinol Metab. 2013.
36. Feigenberg SJ, Marcus Jr RB, Zlotecki RA, et al. Radiation therapy for giant cell tumors of bone. Clin Orthop Relat Res. 2003;411:207–16.
37. Miszczyk L, Wydmański J, Spindel J. Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys. 2001;49(5):1239–42.
38. Malone S, O’Sullivan B, Catton C, et al. Long-term follow-up of efficacy and safety of megavoltage radiotherapy in high-risk giant cell tumors of bone. Int J Radiat Oncol Biol Phys. 1995;33(3):689–94.
39. Ruka W, Rutkowski P, Morysiński T, et al. The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. Int J Radiat Oncol Biol Phys. 2010;78(2):494–8.
40. Nair MK, Jyothirmayi R. Radiation therapy in the treatment of giant cell tumor of bone. Int J Radiat Oncol Biol Phys. 1999;43(5):1065–9.
41. Ghia AJ, Allen PK, Mahajan A, et al. Intracranial hemangiopericytoma and the role of radiation therapy: a population based analysis. Neurosurgery. 2013;72(2):203–9.
42. Sonabend AM, Zacharia BE, Goldstein H, et al. The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis. J Neurosurg. 2014;120(2):300–8.
43. Jalali R, Srinivas C, Nadkarni TD, et al. Suprasellar haemangiopericytoma—challenges in diagnosis and treatment. Acta Neurochir (Wien). 2008;150(1):67–71.
44. Guthrie BL, Ebersold MJ, Scheithauer BW, et al. Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery. 1989;25(4):514–22.